Jnana Therapeutics Announces Dosing of First Participant in Phase 1b Clinical Trial of JNT-517 ...
JNT-517 is a Potential First-in-Class Oral Treatment for PKU; Phase 1b Study Follows Positive Clinical Proof of Mechanism Data in Healthy Individuals
Source: nrtoday.com